A B S T R A C T We have recently described a new animal model of arthritis induced by intradermal injection of a distinct type of collagen found in cartilage (type II collagen). Since immunologic sensitivity to collagen could play a role in the pathogenesis of this type II collagen-induced arthritis in rats, the ability of purified types of native collagens to induce cellular and humoral responses was quantified by antigeninduced tritiated thymidine incorporation into lymphocytes by collagen and passive hemagglutination, respectively. Rats injected intradermally with native heterologous or homologous type II collagens in adjuvant developed type-specific cellular as well as humoral reactivity. Types I and III collagens were less immunogenic than was type II. The latter collagen induced brisk cellular and humoral responses that were equivalent whether complete Freund's adjuvant or incomplete Freund's adjuvant were employed. Both responses could be induced by native type II collagens modified by limited pepsin digestion, indicating that they are not attributable to determinants in the telopeptide regions of the molecule. Thus, these studies demonstrate the unique immunogenic as well as arthritogenic properties of the type II collagen molecule and indicate that both result from a helical conformation of its structurally distinct a-chains. Further, they suggest that type II collagen may, by humoral or cellular mechanisms, provoke or perpetuate inflammation in other arthritic diseases.
A B S T R A C T We have recently described a new animal model of arthritis induced by intradermal injection of a distinct type of collagen found in cartilage (type II collagen). Since immunologic sensitivity to collagen could play a role in the pathogenesis of this type II collagen-induced arthritis in rats, the ability of purified types of native collagens to induce cellular and humoral responses was quantified by antigeninduced tritiated thymidine incorporation into lymphocytes by collagen and passive hemagglutination, respectively. Rats injected intradermally with native heterologous or homologous type II collagens in adjuvant developed type-specific cellular as well as humoral reactivity. Types I and III collagens were less immunogenic than was type II. The latter collagen induced brisk cellular and humoral responses that were equivalent whether complete Freund's adjuvant or incomplete Freund's adjuvant were employed. Both responses could be induced by native type II collagens modified by limited pepsin digestion, indicating that they are not attributable to determinants in the telopeptide regions of the molecule. Thus, these studies demonstrate the unique immunogenic as well as arthritogenic properties of the type II collagen molecule and indicate that both result from a helical conformation of its structurally distinct a-chains. Further, they suggest that type II collagen may, by humoral or cellular mechanisms, provoke or perpetuate inflammation in other arthritic diseases. INTRODUCTION In the past 8 (1) . Type II collagen is localized to cartilage (2) and possibly the vitreous, retina (3) , and cornea (4) of the eye. Biochemical techniques have also been devised which allow these collagens to be solubilized from tissues in a highly purified native state (1) . Thus, by use of these collagen preparations, it is now possible to test the hypothesis proposed by Steffen and Timpl (5) that type-specific immunologic responses to collagen may play a role in inciting or perpetuating inflammation occurring in the connective tissue diseases. Humoral reactions to collagen have been demonstrated in patients with rheumatoid arthritis (5) (6) (7) (8) (9) (10) (11) (12) . By delineating a unique animal model of autoimmunity, type II collagen-induced arthritis in rats (13), we have provided further support for this hypothesis.
As we recently reported (13) (14) .
In this paper we present data that demonstrate that all of these collagens can induce type-specific cellular as well as humoral immunologic responses in rats. The magnitude of both antibody production to type II collagen and antigen-induced tritiated thymidine ([3H]TdR) incorporation by lymphocytes correlates with the occurrence of arthritis. Moreover, there is a close temporal association between the development of cellular sensitivity to type II collagen and the onset of arthritis. These findings are consistent with the hypothesis that type-specific immunologic hypersensitivity to the cartilage type of collagen may be involved in the etiology of the disease.
METHODS
Rats. Outbred female Wistar rats (Harlan, Indianapolis, Ind., and Charles River Breeding Laboratories, Wilmington, Mass.) weighing 175-225 g were used.
Collagens. Human types I, II, and III collagens, human and rat al(I), a2, and al(II) and human al(III) chains, and a crude proteoglycan complex from human cartilage were prepared by methods previously described (13) . Human and rat types I and II and human type III molecules were pepsin-modified to enhance solubility. Chick types I and II were prepared as tropocollagens from lathyritic animals. Chick al (II) chains were also employed. Purity of each preparation was assessed by carboxymethyl cellulose chromatography and amino acid analysis (13) . No proteoglycan contamination in any preparation could be detected by uronic acid assay (15) . Hydroxyproline analyses (16) were used to determine the concentrations of soluble collagen used for immunizations or coating red cells for hemagglutination studies.
Immunizations. The immunization regimens were outlined in the previous paper (13) and used either CFA (Difco Laboratories, Detroit, Mich.) containing Mycobacteria butyricum (0.5 mg/ml) or ICFA (Difco Laboratories). Control immunizations with the CFA at this dose and injection site failed to induce adjuvant arthritis in 30 rats. When CFA containing 1.0 mg M. tuberculosis per ml oil (CFA H37Ra, Difco Laboratories) was injected into the tail, adjuvant arthritis could be induced (13) . Booster doses consisting of collagen without adjuvant were given intraperitoneally on day 21 unless otherwise noted. Antisera were collected by distal tail amputation or cardiac puncture under ether anesthesia 42 days after primary immunization unless otherwise specified.
Antibody detection. Antibodies were quantified by a passive microhemagglutination technique involving glutaraldehyde fixation of human (blood group 0, Rh+) erythrocytes sensitized with the collagen preparations (17, 18 sion of cells was sensitized by the addition of an equal volume of 0.1 M calcium acetate containing the following collagen concentrations: 0.1% human types I and III; 0.02% human, chick, and rat type II; and 0.05% chick or rat type I or a-chains. Higher collagen concentrations tended to cause nonspecific agglutination. Sodium azide, 0.1%, was routinely used as a preservative and 0.1% bovine serum albumin as a stabilizer. Cells were stored at 4°C and used within 2 wk after preparation. Repeat testing of standard antisera showed no fall in titer during this time. Titrations were performed in round-bottom plastic microtiter plates (Cooke Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, Va.) and were compared with control cells not coated with collagen. Mean titers are expressed as serial -log2 dilutions ±SEM.
Mercaptoethanol reduction. 0.25 ml of antisera from rats receiving only primary immunization were treated with 0.05 ml of 0.2 M mercaptoethanol in 0.25 M Tris-HCl buffer, pH 8.6, for 1 h at 37°C (19) . Immediately after incubation, hemagglutination titers ofthe treated sera were compared with those of the sera treated with buffer alone.
Peripheral blood mononuclear cell cultures. Cellular sensitivity to collagen was assessed by antigen-induced [3H]TdR incorporation by peripheral blood mononuclear cells. 3-4 ml of blood with heparin were obtained by cardiac puncture under ether anesthesia. Mononuclear cells were isolated by diluting blood 1:2 with Hanks' balanced salt solution (Microbiological Associates, Bethesda, Md.) and layering over FicollHypaque or lymphocyte separation medium (Bionetics Laboratory Products, Kensington, Md.) gradients. After centrifugation, approximately 4-6 x 106 mononuclear cells per original milliliter of blood could be obtained. After two washings in media, cells were counted with a hemocytometer or a Coulter Counter (Coulter Electronics Inc., Hialeah, Fla.). They were then suspended at a concentration of 106/ml in RPMI 1640 (Microbiological Associates) supplemented with penicillinstreptomycin (100 U and 100 ,ug/ml, respectively) made to contain 8% fresh rat serum. Viability, tested by exclusion of 0.2% trypan blue, was greater than 95%.
Initially, 1.0-ml aliquots were cultured in triplicate in Falcon 3033 tubes (Falcon Plastics, Division of BioQuest, Oxnard, Calif.) and harvested with a Millipore sampling manifold (Millipore Corp., Bedford, Mass. Likewise, incorporation induced by sensitization with homologous or heterologous type II collagen was also similar (mean SI 3.1±0.4 for 7 rats injected with rat type II, mean 7.0±1.8 for 30 rats injected with human or chick type II, P not significant). Finally, the magnitude of incorporation induced by the specific species of heterologous type II collagen used for sensitization was similar in rats injected with human (pepsin-modified) or chick (tropocollagen) type II collagen (mean SI 6.3 ± 1.9 for 24 rats injected with human type II vs. 9.5±5.0 for 6 rats injected with chick type II, P not significant). Thus, the cellular response to type II collagen was not attributable to the telopeptide portions ofthe molecule.
Lymphocytes from some rats injected with human types I and III collagens or chick al(II) chains in CFA also showed in vitro sensitivity to these respective collagens (Table II) . Cells from 5 of 9 rats injected with type I and 4 of 8 rats with type III, both in CFA, exhibited enhanced [3H]TdR incorporation (SI : 2) to their sensitizing collagen (mean SI 3.0±0.8 and 3.0 ±0.9, respectively) when tested 42-70 days later. SI 2 were found in cells from 3 of 10 rats injected with al(II) chains in CFA (mean SI 1.3±0.3). In contrast to Time-course studies. We next assessed whether the onset of humoral or cellular sensitivity to type II collagen was temporally related to the development of arthritis. As shown in Fig. 1 and Table IV, 22 Wistar rats were studied on the day of onset ofclinically recognizable arthritis which developed 14-22 days (mean 18±0.6) after injection of human type II collagen in CFA. 22 rats which remained nonarthritic during the usual time of onset of disease were studied as controls 21-24 days postinjection.
[3H]TdR incorporation by unstimulated lymphocytes did not differ significantly in either group (mean 914±130 cpm arthritic rats vs.
1,124±301 nonarthritic rats). Peripheral blood mononuclear cells from arthritic rats yielded a higher mean SI when cultured with type II collagen than cells from nonarthritic rats (6.1 ± 1.6 vs. 1.1+0. 1, P < 0.004). Higher mean -log2 antibody titers were also observed in arthritic rats (8.5±0.3 vs. 4.3+0.6, P < 0.0001). Fig. 1 
DISCUSSION
Early studies of the antigenic determinants on native collagen utilized rabbit antisera to heterologous type I and indicated that determinants were primarily located in the nonhelical telopeptide regions of the molecule (20) (21) (22) . Later work, however, showed that the humoral response to heterologous native type I collagen in rats (18, 23, 24) and mice (25) is restricted to helical determinants, since appreciable cross-reactivity of the antisera with the constituent a-chains was not observed. Recent evidence demonstrates type-specificity for hemagglutinating antibodies elicited by injection of native heterologous types I and II collagens in CFA (24, 25) . This again is dependent on a helical conformation of the proteins. Humoral responsiveness to type I and type II bovine collagen differed in several inbred mouse strains, suggesting separate genetic control of antibody production to these different immunogens (25, 26) .
Cellular sensitization to collagen has previously been reported only in guinea pigs injected with type I collagen and CFA (27) (28) (29) (30) (31) (32) . Either heterologous (28) (29) (30) (31) or homologous (32) type I collagens in the native (29) or denatured (30) state could induce a cellular response. Guinea pigs injected with native type I collagen showed appreciable skin test reactivities and migration inhibitory factor production when challenged with either the native or denatured protein (29, 32) . This cross-reactivity and the ability of denatured collagen to induce cellular sensitivity indicate that helical determinants were not involved in eliciting these responses. Extensive cross-reactivities were also found between mammalian skin collagens (28) (29) (30) . Use of CFA appeared to be essential to elicit cellular sensitivities (29, 32) . In fact, an initial injection of heterologous type I collagen emulsified in ICFA specifically suppressed the later induction ofcellular sensitivity to type I collagen when CFA was used (33) . Additional work indicated that the humoral response induced by the initial injection did not appear to function in the suppression of cellular sensitivity (33, 34 (14) .
The mechanism by which arthritis is produced by type II collagen injection is not known, although preliminary evidence presented here supports the hypothesis that immunologic hypersensitivity may be involved. The specificity of the immune response to type II collagen parallels its unique arthritogenicity. We have recently achieved adoptive transfer of type II collagen-induced arthritis by sensitized spleen and lymph node cells, more directly implicating immunologic hypersensitivity to type II collagen in the pathogenesis of the disease.2 Further, we have recently demonstrated
